Danaher (DHR) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 20, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Matthew McGrew, President sold 17,385 shares at $235.69 ($4.1M).
- Trade date
- Nov 9, 2026
- Disclosed to the SEC
- Nov 10, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All DHR insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
DHR insider transactions (Form 4)
Open-market purchases and sales. 83 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 10SEC | Matthew McGrewPresident | Sell | 17,38512,674 held (−58%) | $235.69 | $4.1M | -3.6% | — |
| Nov 10SEC | Gregory M. MilosevichPresident | Sell | 2,10022,367 held (−9%) | $230.62 | $484K | -1.5% | — |
| Oct 29SEC | Matthew McGrewPresident | Sell | 15,60312,674 held (−55%) | $236.09 | $3.7M | -3.8% | — |
| Oct 29SEC | Matthew McGrewPresident | Sell | 14,15112,674 held (−53%) | $235.35 | $3.3M | -3.5% | — |
| Oct 29SEC | Christopher BoudaVp, Chief Accounting Officer | Sell | 4,3459,107 held (−32%) | $234.54 | $1.0M | -3.1% | — |
| Oct 29SEC | Christopher BoudaVp, Chief Accounting Officer | Sell | 3,2539,107 held (−26%) | $234.58 | $763K | -3.1% | — |
| Aug 24SEC | Rainer BlairCEO, President | Sell | 39,1937,755 held (−83%) | $218.73 | $8.6M | +3.9% | — |
| Aug 24SEC | Rainer BlairCEO, President | Sell | 11,30746,948 held (−19%) | $217.77 | $2.5M | +4.3% | — |
| Aug 24SEC | Rainer BlairCEO, President | Sell | 7,755 | $219.35 | $1.7M | +3.6% | — |
| May 4SEC | Alan G. SpoonDirector | Sell | 1,358124,094 held (−1%) | $174.67 | $237K | +30.1% | — |
| Feb 20SEC | Gregory M. MilosevichPresident | Sell | 1,3205,099 held (−21%) | $208.01 | $275K | +9.2% | — |
| Nov 26SEC | Mitchell P. RalesChair | Sell | 35,899854,726 held (−4%) | $230.27 | $8.3M | -1.3% | — |
| Nov 26SEC | Mitchell P. RalesChair | Sell | 4,726850,000 held (−1%) | $231.19 | $1.1M | -1.7% | — |
| Nov 19SEC | Teri ListDirector | Sell | 3,29820,762 held (−14%) | $226.50 | $747K | +0.3% | — |
| Nov 13SEC | Mitchell P. RalesChair | Sell | 254,553709,820 held (−26%) | $218.27 | $55.6M | +4.1% | — |
| Nov 13SEC | Mitchell P. RalesChair | Sell | 133,233576,587 held (−19%) | $219.43 | $29.2M | +3.5% | — |
| Nov 13SEC | Mitchell P. RalesChair | Sell | 25,855964,373 held (−3%) | $217.64 | $5.6M | +4.4% | — |
| Nov 13SEC | Mitchell P. RalesChair | Sell | 23,359553,228 held (−4%) | $220.15 | $5.1M | +3.2% | — |
| Nov 13SEC | Matthew McGrewCFO | Sell | 16,17220,062 held (−45%) | $214.62 | $3.5M | +5.9% | — |
| Nov 13SEC | Brian W. EllisPresident | Sell | 14,66714,553 held (−50%) | $219.23 | $3.2M | +3.6% | — |
| Nov 13SEC | Brian W. EllisPresident | Sell | 7,10914,553 held (−33%) | $219.21 | $1.6M | +3.7% | — |
| Nov 12SEC | Georgeann CoucharaSvp, Human Resources | Sell | 4,1763,623 held (−54%) | $210.44 | $879K | +8.0% | — |
| Nov 12SEC | Georgeann CoucharaSvp, Human Resources | Sell | 9982,625 held (−28%) | $210.31 | $210K | +8.0% | — |
| Nov 4SEC | Mitchell P. RalesChair | Sell | 308,4231,281,805 held (−19%) | $215.67 | $66.5M | +5.4% | — |
| Nov 4SEC | Mitchell P. RalesChair | Sell | 223,4491,058,356 held (−17%) | $216.26 | $48.3M | +5.1% | — |
| Nov 4SEC | Mitchell P. RalesChair | Sell | 68,128990,228 held (−6%) | $217.17 | $14.8M | +4.6% | — |
Similar past setups: not applicable. DHR has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with DHR in the Research Lab
DHR has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Danaher insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $36.0M of DHR stock on the open market; P/E 38.2 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
DHR insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $13.4M | 6 |
| Q3 2026 | — | 0 | $12.7M | 3 |
| Q2 2026 | — | 0 | $237K | 1 |
| Q1 2026 | — | 0 | $275K | 1 |
| Q4 2025 | — | 0 | $245M | 15 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Danaher Corporation insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $36.0M. 0 of 26 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
DHR earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 21, 2026 | +1.4% | None | +2.5%S&P -0.7% | pending |
| Jul 21, 2026 | +1.6% | None | -10.9%S&P +0.7% | +22.2% |
| Apr 21, 2026 | +2.3% | None | -5.9%S&P +0.4% | -6.5% |
| Jan 28, 2026 | -1.4% | None | -6.8%S&P -0.2% | -4.1% |
| Jan 12, 2026 | +3.1% | None | -1.2%S&P -0.0% | -8.8% |
| Oct 21, 2025 | -3.1% | None | +4.7%S&P -0.5% | +4.3% |
| Jul 22, 2025 | -7.4% | None | +5.2%S&P +0.9% | +7.0% |
| Apr 22, 2025 | +1.8% | None | +6.1%S&P +4.2% | -6.0% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
DHR short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded DHR
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +25.7% |
Insiders at Danaher Corporation
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Mitchell P. RalesChair | — | $235M | Oct 14, 2026 | — | — |
| Matthew McGrewPresident | — | $14.6M | Nov 10, 2026 | — | — |
| Rainer BlairCEO, President | — | $12.7M | Aug 24, 2026 | — | — |
| Brian W. EllisPresident | — | $4.8M | Feb 6, 2026 | — | — |
| Christopher BoudaVp, Chief Accounting Officer | — | $1.8M | Oct 29, 2026 | — | — |
| Georgeann CoucharaSvp, Human Resources | — | $1.1M | May 19, 2026 | — | — |
| Gregory M. MilosevichPresident | — | $759K | Nov 17, 2026 | — | — |
| Teri ListDirector | — | $747K | May 19, 2026 | — | — |
| Alan G. SpoonDirector | — | $237K | May 19, 2026 | — | — |
| Jonathan LeikenGeneral Counsel | — | — | Nov 17, 2026 | — | — |
| Matthew E. GuginoCFO | — | — | Nov 17, 2026 | — | — |
| Montgomery Julie A. SawyerCEO, President | — | — | Nov 17, 2026 | — | — |
| Shashanka MuppaneniSvp, Chief Strategy Officer | — | — | Nov 17, 2026 | — | — |
| Heathre T. MolerSvp, Chief Hr Officer | — | — | Nov 17, 2026 | — | — |
| Daniel L. ComasDirector | — | — | Nov 17, 2026 | — | — |
| Robert HershbergDirector | — | — | Nov 17, 2026 | — | — |
| Steven M. RalesChair | — | — | Oct 14, 2026 | — | — |
| Jose-Carlos Gutierrez-RamosSvp, Chief Science Officer | — | — | Aug 6, 2026 | — | — |
| Christopher Paul RileyPresident | — | — | Aug 6, 2026 | — | — |
| Elias A. ZerhouniDirector | — | — | Jul 16, 2026 | — | — |
| Linda FillerDirector | — | — | Jul 16, 2026 | — | — |
| Charles W. LamannaDirector | — | — | May 19, 2026 | — | — |
| Feroz DewanDirector | — | — | May 19, 2026 | — | — |
| A. Shane SandersDirector | — | — | May 19, 2026 | — | — |
| Raymond C. StevensDirector | — | — | May 19, 2026 | — | — |
| R. Bradley GraySvp Strategic Development | — | — | Mar 3, 2026 | — | — |
Board links: companies that share insiders with DHR
Directors and executives who filed Form 4s for DHR and another company in the last 12 months.
- VLTOVeralto Linda Filler Director here · Director at VLTO · latest filing Jul 17, 2026Daniel L. Comas Director here · Director at VLTO · latest filing Nov 17, 2026
- ADPTAdaptive Biotechnologies Robert Hershberg Director here · Director at ADPT · latest filing Nov 17, 2026
- CVLTCommvault Systems A. Shane Sanders Director here · Director at CVLT · latest filing Aug 10, 2026
- ETREntergy Brian W. Ellis President here · Director at ETR · latest filing Sep 2, 2026
- FTVFortive Daniel L. Comas Director here · Director at FTV · latest filing Nov 17, 2026
- LULULululemon Athletica Teri List Director here · Director at LULU · latest filing Jun 29, 2026
- MSFTMicrosoft Teri List Director here · Director at MSFT · latest filing Sep 8, 2026
- RXRXRecursion Pharmaceuticals Robert Hershberg Director here · Director at RXRX · latest filing Nov 17, 2026
- VVisa Teri List Director here · Director at V · latest filing May 19, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
DHR stock: common questions
Are Danaher Corporation insiders buying DHR stock?
No. No Danaher Corporation insider reported an open-market purchase of DHR in the past 12 months.
Are Danaher Corporation insiders selling DHR stock?
6 insiders reported sales worth $36.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is DHR's P/E ratio?
DHR trades at about 38.2 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is DHR's 52-week range?
Over the past year DHR has traded between $161.29 and $240.61. It last closed at $227.22 on Nov 19, 2026.